Varinos is a clinical test company developing and providing new genomic test services.
We provide clinical tests in the field of reproductive medicine and obstetrics and gynecology, such as the "Endometrial Microbiome Test" which has been made possible by ourlatest genome technology to detect extremely small amounts of bacteria, and "Preimplantation Genetic Test" which examines the genes and chromosomes of an embryo before conception to check for abnormalities.
Research and development area
In addition to the fields of reproductive medicine and obstetrics and gynecology, we are expanding the use and potential of genomic medicine to include cancer and neonatal genetic diseases. We are developing unprecedented new genomic tests for the era of genomic medicine, where diagnosis is based on the diversity of genomes.
Our goal is to standardize clinical test services using next-generation sequencers (NGS) and to provide clinical sequencing tests to patients in a timely manner.
Genome is a word synthesized from genes and chromosomes; it is all the genetic information in DNA. Genome information is like a blueprint for building the body.Genome medicine is to diagnose and treat diseases efficiently and effectively based on the comprehensive genomic information.
*NGS：Next Generation Sequencer
Next-generation sequencer (NGS) is an instrument that can read thousands to millions of DNAsequences at high speed. It is possible to analyze the genome (genetic information) at an overwhelmingly low cost and in a short time.
Swift Next-Gen Sequencing by Specialists
The " Endometrial Microbiome Test," developed by our company, is the world's first practical application of microbiome technology in the infertility field using a next-generation sequencer as a clinical test.
Operation using in-house facilities
Varinos Laboratory is a registered clinical laboratory (No. 177, Koto-ku, Tokyo), and implements unique quality control (QC) at key points in the Test process to minimize human error and ensure thorough accuracy control.
Research and development by our genome analysis specialists
Our experienced specialists in next-generation sequencing develop new genomic tests. We are actively engaged in collaborative research with universities, research institutes, and IVF clinics throughout Japan.
We develop and provide new clinical tests mainly in the fields of reproductive medicine and obstetrics and gynecology.
Endometrial Microbiome Test business has continued since the company was founded.
Endometrial microbiome Test uses specimens collected from the vagina and uterus to examine the types and percentages of bacteria in the uterus.Learn more about Endometrial Microbiome Test
Lactoferrin, present in breast milk, plays a vital role in safeguarding both babies' and mothers' bodies from within. Varinos offers lactoferrin supplements.
*We have obtained a patent for the invention of the use of lactoferrin for intrauterine flora.Learn more about Lactoferrin
Preimplantation Embryo Genome Test and Analysis
We offer the Preimplantation Genome Test (PGT-A), which allows us to evaluate the chromosomes of embryos after IVF or ICSI before implantation. This is a test project that uses genome analysis to examine chromosomal abnormalities, which are believed to be the cause of miscarriages before implantation.
Varinos was founded by CEO Sakuraba and co-founder Nagai, who had extensive experience in the field of genetic testing and next-generation sequencing. Sakuraba had introduced the first new type of prenatal diagnosis (NIPT) in Japan and was involved in market development for genetic tests (NIPT and PGS) in obstetrics and gynecology. On the other hand, Nagai was a specialist in genetic statistical analysis and database construction. Having previously worked together at Illumina, a company that develops and markets next-generation sequencers, they established Varinos in 2017.
Their motivation for founding Varinos stemmed from the observation that Japan lacked genome test companies, and tests that were commonplace in other countries were not available in Japan. Despite Japan's world-class research results in genomics, no company provided genomic tests as clinical tests in the medical field. This led Sakuraba and Nagai to embark on developing genomic tests in Japan, particularly focusing on providing services in the field of obstetrics and gynecology, with the aim of aiding patients in infertility treatment and supporting doctors in reproductive medicine who desired genomic testing but lacked access to it.
The name "Varinos" is derived from "Variant for Diagnose," reflecting Nagai's aspiration to contribute to people's health by integrating genomics into society.
"Our future goal is to be there for everyone, weaving the future of families."
In the realm of reproductive medicine, where the success rate of a single IVF cycle is typically 10-30%, Varinos has dedicated efforts to develop and enhance genomic technology to increase success rates. Their vision is to create a world where fertility treatment patients can undergo reproductive medicine with an outstanding success rate of 70% to 80%. With this objective in mind, Varinos is committed to reducing the physical, financial, and psychological burdens faced by fertility treatment patients. They aim to support as many patients as possible, helping them pave the way for their family's future.
Currently, our services primarily revolve around fertility treatment and reproductive medicine. However, this marks just the beginning of our journey. The potential of genome tests to shape the future of patients extends to various other domains, including neonatal diseases and cancer, where its capabilities can be harnessed for significant advancements.
Emphasizing genome tests as our core foundation, we are dedicated to progressing and offering testing services across a diverse range of fields. Our commitment remains unwavering as we strive to unlock the full potential of genomic technology and contribute to the well-being of patients in numerous areas.
Founder and CEO
Received a Ph.D. (Science) from Saitama University in the post-doctoral program,Major in Genetics
RIKEN Center for Genomic Sciences,Genome Related National Projects
St. Jude Children's Hospital, USA
Basic research on cancer-related genes
Senior Manager, Laboratory Technology Department, GeneTech Corporation
Development of detection method of chromosome aneuploidy using maternal blood nucleated erythrocytes
Introduction of NIPT in Japan
Exective Clinical Sales Specialist, Illumina, Inc.
NIPT and PGT-A related technical sales
Next generation sequencing for medical applications
Founder and CEO, Varinos Inc. (present post)
Director, COO and CSO
Graduated from Hokkaido University Faculty of Veterinary Medicine (Veterinarian)
Astellas Pharma Inc.
Responsible for clinical development in Japan and other Asian countries
Business Producer, Dream Incubator Inc.
Engaged in consulting services for large companies and policy making support for government agencies.
Participated in the launch of the new Medical Marketer (MM) business as a main member and established the service.
Executive Officer, Business Development, Preferred Networks, Inc.
Director, COO and CSO, Varinos Inc. (current position)
PwC Arata Limited Liability Audit Corporation (passed the Certified Public Accountant Examination)
Worked as an in-charge at a megabank to support internal control evaluation
Director and General Manager, Corporate Administration Division, GA technologies Inc.
Achieved Mothers IPO in the 5th year after establishment and was in charge of M&A and IR after listing
Director and CFO, Caster Inc.
Director and CFO, RECLO Inc.
Director, CFO, Varinos Inc. (current position)
- Outside Director Tatsuzo Ishigami
- Outside Director Yutaro Kasai
- Outside Director Hiroyuki Misawa
- Outside Director Jun Narimatsu
- Outside Director Hiroko Kimura
- Outside Director Huimin Wang
- Auditor Masanori Ishikawa
- Auditor Yoko sano
Feb. 20, 2017.
Contract analysis of clinical laboratories and development of genomic tests
1-1-20 Aomi, Koto-ku, Tokyo DiverCity Tokyo Office Tower 21F
+81 3 5422 6501